Involving A Micro-organism Or Cell Membrane Bound Antigen Or Cell Membrane Bound Receptor Or Cell Membrane Bound Antibody Or Microbial Lysate Patents (Class 435/7.2)
Abstract: The present invention relates to kits designed for the collection of stool samples and methods of analyzing those samples for biological markers of maldigestion, inflammation, and imbalanced gut flora.
Abstract: The present invention relates to an N-terminal cysteine-tagged Streptococcal protein G variant. Since the variant binds in a directional manner to a surface of a biochip or a biosensor, the variant provides a biochip and a biosensor having an improved antibody-immobilizing capability, compared with an untagged protein G variant.
Type:
Grant
Filed:
June 20, 2007
Date of Patent:
September 24, 2013
Assignee:
Korea Research Institute of Bioscience and Biotechnology
Abstract: The present invention provides a method for specifically detecting a Mycobacterium tuberculosis complex-specific secretory protein MPT64 antigen in a biological sample, whereby diagnosis of infection with Mycobacterium tuberculosis is carried out rapidly and safely with higher accuracy than before. An antibody that recognizes an epitope for MPB64 located in any one of amino acid sequences of SEQ ID NOS: 2 to 4, particularly a monoclonal antibody was obtained. Thus, an immunoassay using the antibody, particularly a sandwich immunoassay using first and second antibodies to MPB64, particularly an immunochromatographic assay and an immunochromatographic test strip are provided. A biological sample can be rapidly subjected to the immunoassay without culturing or after culturing for a time before Mycobacterium tuberculosis complex bacteria in the sample substantially start to grow.
Abstract: Peptide sequences that specifically bind infectious prion protein for the generation of antibodies and therapeutic agents are disclosed herein.
Type:
Grant
Filed:
September 30, 2009
Date of Patent:
September 24, 2013
Assignee:
The United States of America, as represented by the Secretary of Agriculture
Abstract: Compositions and methods of treatment for abnormal bone density are disclosed based upon the finding that sclerostin must be bound to glypican in order to inhibit bone deposition. Methods for identifying agents that inhibit the glypican-sclerostin interaction are disclosed for treatment of bone deposition disorders. Diagnostic methods are also disclosed.
Abstract: The present invention provides assays and devices for detection of substances in liquid samples. The assays and devices utilize passive diffusion between a porous material and a porous membrane containing a specific binding pair member to enable detection of the substance of interest.
Type:
Grant
Filed:
June 29, 2011
Date of Patent:
September 24, 2013
Assignee:
Techlab, Inc.
Inventors:
James H. Boone, David M. Lyerly, Tracy D. Wilkins
Abstract: Inflammatory state in a subject is assayed by determining the level of expression of A3 adenosine receptor (A3AR) in white blood cells (WBC), e.g. circulating WBCs, from the subject. A high level of expression of A3AR is indicative of an inflammatory state in the subject. This assay can be used for determining the severity of inflammation in a subject and monitoring the efficacy of anti-inflammatory treatment. Also, the level of expression may be used for selecting patients to receive an anti-inflammatory treatment that comprises an A3AR agonist.
Type:
Grant
Filed:
June 21, 2010
Date of Patent:
September 24, 2013
Assignee:
Can-Fite Biopharma Ltd.
Inventors:
Pnina Fishman, Sara Bar-Yehuda, Lea Madi
Abstract: Biosensor comprising an activatable acceptor fluorogen linked via a linker to a donor which transfers energy to the fluorogen on detecting an analyte wherein the fluorogen component reacts and a 100 fold increase in intensity results when the fluorogen interacts non-covalently with an activator e.g. fluorogen activator peptide.
Type:
Application
Filed:
May 25, 2011
Publication date:
September 19, 2013
Applicant:
CARNEGIE MELLON UNIVERSITY
Inventors:
Alan Waggoner, Marcel P. Bruchez, Brigitte F. Schmidt, Subhasish K. Chakraborty
Abstract: The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.
Type:
Grant
Filed:
November 2, 2012
Date of Patent:
September 17, 2013
Assignees:
Singulex, Inc., The Regents of the University of California
Inventors:
Philippe Goix, Robert Puskas, John Todd, Richard Livingston, Douglas Held, Allan H. B. Wu
Abstract: The present invention discloses a process for simple and rapid detection and identification of molecular mimicry or mimic antigens or molecules existing in/on humans, animals and plants. The molecular mimicry can be related to infections, autoimmune diseases, cancers, obesity and other disorders. Therefore, novel methods for the diagnosis, prevention, and treatment of infections, autoimmune diseases, cancers, obesity and other disorders obtainable based on these mimic antigens or molecules can be developed. Furthermore, the present invention also reveals a new functional mechanism of vaccine and passive immunity and novel vaccines obtainable based on the new mechanism.
Abstract: Methods for identifying individuals who are not yet diabetic (pre-diabetic), but who are at significant risk of developing diabetes, such as type 2 diabetes, are disclosed herein. Methods are also provided for the identification of diabetic subjects. Also disclosed are methods for identifying individuals with diabetic complications. The methods include the identification of an overall glycosylation profile of proteins in a biological fluid, such as saliva, urine, or serum. In some examples, the methods include determining the amount of one or more protein in a biological fluid or determining the glycosylation pattern of one or more proteins in a biological fluid.
Type:
Grant
Filed:
April 26, 2012
Date of Patent:
September 10, 2013
Assignee:
DiabetOmics, LLC
Inventors:
Srinivasa R. Nagalla, Charles T. Roberts
Abstract: This document relates to methods and materials involved in assessing samples for enzyme-nucleic acid complexes. For example, methods and materials for using antibodies to determine the presence, absence, or amount of enzyme-nucleic acid complexes (e.g., human topoisomerase I-DNA complexes) in a sample (e.g., a biological sample such as a tissue biopsy) are provided.
Type:
Grant
Filed:
May 19, 2011
Date of Patent:
September 10, 2013
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: The present invention discloses methods of reducing non-specific interactions of interfering species present in a sample in metallic nanoparticle-based assays, thereby increasing the sensitivity of these assays. In particular, the methods entail neutralizing the chemical reactivity of functional groups present in interfering species by addition of a neutralizing agent, such as an alkylating agent or heavy metal ion. The methods are especially useful in assays for the detection of analytes in biological samples. Reagent kits and assay mixtures for the practice of the described methods are also disclosed.
Type:
Grant
Filed:
July 9, 2009
Date of Patent:
September 10, 2013
Assignee:
Abaxis, Inc.
Inventors:
Rajesh K. Mehra, Vincent Chiang, Kenneth Aron
Abstract: The present invention relates to use of a digital holographic microscopy and imaging setup and a method of digital holographic microscopy and imaging for detecting molecules or structures stained or labelled to at least one cell or conjugated to antibodies which are bound either directly to said at least one cell or indirectly via another or several antibodies in a chain bound to said at least one cell.
Type:
Application
Filed:
February 7, 2011
Publication date:
September 5, 2013
Applicant:
Phase Holographic Imaging PHI AB
Inventors:
Mikael Sebesta, Kersti Alm, Anders Långberg, Anna Molder, Johan Persson, Lennart Gisselsson
Abstract: A method for detecting at least one antibody directed against at least one primate immunodeficiency virus in a biological sample that includes contacting a biological sample with (i) at least one detection multiple antigenic peptide comprising a portion of an immunodominant region of a transmembrane protein of a primate immunodeficiency virus and (ii) at least one differentiation multiple antigenic peptide comprising a portion of a V3-loop of an envelope protein of a primate immunodeficiency virus. Also disclosed is an enzyme immunoassay that includes a first substrate to which are bound at least one of the detection multiple antigenic peptides and a second substrate to which are bound at least one of the differentiation multiple antigenic peptides.
Type:
Grant
Filed:
March 4, 2010
Date of Patent:
September 3, 2013
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Marcia L. Kalish, Clement B. Ndongmo, Chou-Pong Pau, William M. Switzer, Thomas M. Folks
Abstract: The present invention relates to the field of diagnosis and therapy of hematological malignancies based on the tumor antigen FMR1NB (also called NY-SAR-35, Cancer/testis antigen 37 or Fragile X mental retardation 1 neighbor protein) and agents specifically targeting this antigen or cells expressing the same, e.g., antibodies. The inventors were able to prove that the molecule is expressed on the cell surface and thus represents a particularly advantageous target in cancer therapy and vaccination. Surprisingly, FMR1NB was found to be associated with hematological malignancies, e.g. acute myeloid leukemia (AML) or chronic myeloid leukemia (CML).
Abstract: The present invention provides the amino acid and polynucleotide sequences of the transcobalamin receptor, as well as modulators of the transcobalamin receptor. Accordingly, the present invention provides compositions and methods for the treatment and prevention of diseases and disorders associated with cobalamin deficiency, including compositions and methods that promote cobalamin uptake. In addition, the present invention provides compositions and methods for the detection, treatment, and prevention of diseases associated with deregulated cell growth, including, e.g., cancer and autoimmune disorders, including compositions and methods that inhibit cobalamin uptake.
Type:
Grant
Filed:
April 5, 2007
Date of Patent:
September 3, 2013
Assignee:
The Research Foundation of State University of New York
Abstract: The present invention relates to agonists of the human bitter-taste receptors hTAS2R14, hTAS2R10 and hTAS2R4 and their role in bitter taste transduction. The invention also relates to methods for identifying molecules that modulate, e.g. suppress, or enhance hTAS2R14, hTAS2R10 and hTAS2R4 bitter taste transduction or bitter taste response.
Abstract: The invention generally relates to the field of immunochemistry including antibody therapy, diagnostics, and basic research and specifically relates to the area of selecting affinity molecules such as natural antibodies, including artificial antibodies, antibody mimics, and aptamers. The invention relates particularly to a method of selecting affinity molecules using a homogeneous noncompetitive assay in a high throughput process.
Abstract: The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds. The invention further relates to the use of these receptors in assays for identifying ligands that modulate the activation of these taste receptors by these bitter ligands and related compounds and which may be used as additives and/or removed from foods, beverages, cosmetics and medicinals in order to modify (block) T2R-associated bitter taste.
Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.
Type:
Grant
Filed:
August 19, 2011
Date of Patent:
September 3, 2013
Assignee:
Biogen Idec MA Inc.
Inventors:
Christine M. Ambrose, Jeffrey S. Thompson
Abstract: The present invention provides methods of determining a characteristic of a cell, such as cell type, cellular response to a biochemical event, and biological state. The method generally involves detecting membrane movement in a cell to determine a characteristic of a cell. The methods of the invention are useful for applications such as drug screening and diagnostics. The invention further provides databases of cell characteristics, as determined by the instant methods. The invention further provides systems for determining the characteristic of a cell.
Type:
Grant
Filed:
March 9, 2005
Date of Patent:
September 3, 2013
Assignee:
The Regents of the University of California
Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.
Type:
Grant
Filed:
June 12, 2008
Date of Patent:
August 27, 2013
Assignee:
Hansa Medical AB
Inventors:
Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
Abstract: This disclosure relates to methods of predicting and diagnosing preeclampsia and eclampsia in pregnant subjects. These methods include detecting a decrease of soluble c-kit in a sample obtained from the pregnant subject. A significantly reduced concentration of soluble c-kit in the sample as compared to a gestational age-adjusted control indicates that the pregnant subject will develop or has preeclampsia or eclampsia.
Type:
Grant
Filed:
November 29, 2010
Date of Patent:
August 27, 2013
Assignee:
University of Pittsburgh-Of the Commonwealth System of Higher Education
Inventors:
Carl A. Hubel, Janet M. Catov, Robin E. Gandley, James M. Roberts, Augustine Rajakumar
Abstract: The present invention provides a method for reducing undesirable light emission from a sample using at least one photon producing agent and at least one photon reducing agent (e.g. dye-based photon reducing agents). The present invention further provides a method for reducing undesirable light emission from a sample (e.g., a biochemical or cellular sample) with at least one photon producing agent and at least one collisional quencher. The present invention also provides a method for reducing undesirable light emission from a sample (e.g., a biochemical or cellular sample) with at least one photon producing agent and at least one quencher, such as an electronic quencher. The present invention also provides a system and method of screening test chemicals in fluorescent assays using photon reducing agents. The present invention also provides compositions, pharmaceutical compositions, and kits for practicing these methods.
Type:
Grant
Filed:
April 2, 2012
Date of Patent:
August 27, 2013
Assignee:
Life Technologies Corporation
Inventors:
Tom Knapp, Gregory Zlokarnik, Paul Negulescu, Roger Tsien, Timothy Rink
Abstract: The present invention relates to sour taste receptors and compositions and methods thereof. In particular, the present invention provides assays and methods of screening for ligands specific for sour taste receptors. Additionally, the present invention provides methods for screening for accessory proteins and mutations, polymorphisms and other potential sour taste receptor protein mutations that are associated with disease states, and therapeutic agents, ligands, and modulators of such proteins. The present invention also provides compositions and methods for modulating sour taste receptors in vitro and in vivo.
Abstract: The present invention relates to novel uses of the MLN 51 gene or protein. The MLN 51 gene and protein is closely related to the development of rheumatoid arthritis and serve as biomarker and therapeutic target for rheumatoid arthritis, particularly chronic synovitis.
Type:
Grant
Filed:
May 8, 2007
Date of Patent:
August 20, 2013
Assignee:
Creagene Inc.
Inventors:
Jin Ah Jang, Dae Seog Lim, Hyun Soo Lee, Yong Soo Bae
Abstract: Encoded microparticles described are useful in the study of many different biological agents in multiplex assays. For instance, the encoded microparticles may be employed in various co-precipitation assays to purify and/or isolate various analytes of interest. Encoded microparticles may also be used as real-time detectors in many different situations whereby binding of a secreted analyte or contaminating analyte may be detected using various labeling techniques. Further, encoded microparticles may be attached in a specific manner to particular cell types, for instance in a heterogeneous mixture of cells, either fixed in tissue or circulating, to allow identification, localization and/or sorting of the cells in the context of various biological events under various environments or conditions.
Abstract: The invention is directed to aptamers, methods and kits comprising same for detecting Streptococcus pyogenes. The method of screening a subject for Streptococcus pyogenes involves obtaining a body sample from the subject; contacting the sample or a bacterial culture of the sample with an aptamer or a panel of aptamers specific to S. pyogenes; and detecting the presence or absence of S. pyogenes in the sample or the bacterial culture, wherein binding of the aptamer is indicative of the presence of S. pyogenes.
Type:
Grant
Filed:
March 29, 2012
Date of Patent:
August 13, 2013
Assignee:
The Governors of the University of Alberta
Inventors:
X. Chris Le, Camille Hamula, Xing-Fang Li
Abstract: A method of diagnosing in a host infection by or exposure to a mycobacterium which expresses ESAT-6 comprising (i) contacting a population of T cells from the host with one or more peptides or analogues selected from the peptides represented by SEQ ID NO:1 to 11 and analogues thereof which can bind a T cell receptor which recognises any of the said peptides, and (ii) determining whether the T cells of said T cell population recognise the peptide(s) and/or analogue(s). The method may performed in vivo. Peptides and a kit which enable the method to be carried out are provided.
Abstract: A process for treating biological targets in a fluid of a biological organism, including introducing a fluid comprising a biological target to an assembly comprising an inlet connected to receive the fluid and an outlet connected to pass the fluid from the assembly, wherein the assembly comprises a flow chamber for conveying a flow of the fluid, and a capture zone comprising a target-specific binding agent, wherein during flow of the fluid through the flow chamber, the biological target undergoes flux rolling along the target-specific binding agent.
Type:
Grant
Filed:
January 10, 2012
Date of Patent:
August 13, 2013
Assignee:
Biomed Solutions LLC
Inventors:
Patrick R. Connelly, Jeffrey L. Helfer, Andrew W. Custer, Michael B. Kim
Abstract: The field of the present invention is the diagnosis and/or prediction and/or therapy follow-up of bacterial infections in subjects suffering from dyspnea. It is a subject of the present invention to provide a method for the diagnosis and/or prediction and/or therapy follow-up of bacterial infections in subjects suffering from dyspnea.
Abstract: Novel thymidine kinase (TK1) derived peptide consisting of the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 is employed to obtain ligands having specificity to the peptide. The ligand may be an antibody or fragment thereof and may be used in various methods and kits for health screening and the like.
Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to a FGFR2, a FGFR3, a SV2, or any combination thereof, to a governmental or regional regulatory authority.
Type:
Grant
Filed:
May 20, 2009
Date of Patent:
July 30, 2013
Assignee:
Allergan, Inc.
Inventors:
Ester Fernandez-Salas, Birgitte P. S. Jacky, Patton E. Garay, Kei Roger Aoki
Abstract: Methods for identifying individuals who are not yet diabetic (pre-diabetic), but who are at significant risk of developing diabetes, such as type 2 diabetes, are disclosed herein. Methods are also provided for the identification of diabetic subjects. Also disclosed are methods for identifying individuals with diabetic complications. The methods include the identification of an overall glycosylation profile of proteins in a biological fluid, such as saliva, urine, or serum. In some examples, the methods include determining the amount of one or more protein in a biological fluid or determining the glycosylation pattern of one or more proteins in a biological fluid.
Type:
Grant
Filed:
April 26, 2012
Date of Patent:
July 30, 2013
Assignee:
DiabetOmics, LLC
Inventors:
Srinivasa R. Nagalla, Charles T. Roberts
Abstract: Methods are described for detecting reaction components with affect a reaction. Biomolecules such as enzymes can be addressed at the single molecule level in order to discover function, detect binding partners or inhibitors, and/or measure rate constants.
Type:
Grant
Filed:
February 16, 2007
Date of Patent:
July 23, 2013
Assignee:
The Trustees of Tufts College
Inventors:
David R. Walt, David M. Rissin, Hans-Heiner Gorris
Abstract: The transporter that translocates ergothioneine has been identified. Described are methods for identifying and obtaining compounds capable of modulating ergothioneine transport as well as the use of such compounds for the treatment of diseases ergothioneine may be involved in such as autoimmune diseases, in particular rheumatoid arthritis, as well as other diseases arising from cell damage caused by radiation, radicals and relative oxidant species. Furthermore, diagnostic means and methods for determining the presence or susceptibility to such a disease are provided.
Abstract: Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.
Type:
Grant
Filed:
April 29, 2011
Date of Patent:
July 16, 2013
Assignee:
Ventana Medical Systems, Inc.
Inventors:
Jerry W. Kosmeder, Casey A. Kernag, Donald Johnson, Christopher Bieniarz
Abstract: The present invention relates to methods of using GPR119 receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY, such as conditions modulated by stimulation of NPY Y2 receptor (Y2R). Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition modulated by PYY, such as a condition modulated by stimulation of Y2R. Conditions modulated by PYY such as may be a condition modulated by stimulation of Y2R include bone-related conditions, metabolic disorders, angiogenesis-related conditions, ischemia-related conditions, convulsive disorders, malabsorptive disorders, cancers, and inflammatory disorders.
Type:
Grant
Filed:
April 22, 2010
Date of Patent:
July 16, 2013
Assignee:
Arena Pharmaceuticals, Inc.
Inventors:
Zhi-Liang Chu, James N. Leonard, Robert M. Jones
Abstract: A microfluidic-based flow assay and methods of manufacturing the same are provided. Specifically, the microfluidic flow assay includes a micropatterned surface that induces clot formation and an array of microfluidic channels though which blood flows. The micropatterned surface contains two clotting stimuli, one for inducing platelet adhesion and another for inducing the coagulation cascade.
Abstract: The present invention relates to a nucleic acid extracting apparatus, and the nucleic acid extracting apparatus can include a pipe-shaped tube having an open outlet at one side thereof, and a hydrogel column that is provided inside the tube and filters impurities excluding an extraction target material.
Type:
Grant
Filed:
June 22, 2009
Date of Patent:
July 9, 2013
Assignees:
Postech Academy-Industry Foundation, Catholic University Industry-Academic Cooperation Foundation
Abstract: Embodiments of the present disclosure provide for enzyme sensors, protease sensors, methods for producing and using the enzyme and protease sensors, methods of detecting and/or measuring protease activity, methods for characterizing protease cellular activity, fusion proteins, polynucleotides, and vectors corresponding to the enzyme and protease sensors, kits, and the like.
Type:
Grant
Filed:
August 6, 2007
Date of Patent:
July 9, 2013
Assignee:
Georgia State University Research Foundation, Inc.
Abstract: The present invention relates to the method of determining the risk of acute kidney injury comprising determining the amount of a marker selected from VCAN, NRP1, CCL2, CCL19, COL3A1, GZMM or any combination thereof in a sample.
Type:
Application
Filed:
December 4, 2012
Publication date:
July 4, 2013
Inventors:
Rainer Oberbauer, Bernd Mayer, Paul Perco, Alexander Kainz
Abstract: Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to glycodelin. Monoclonal antibodies having the binding characteristics of a glycodelin antibody of the invention and monoclonal antibodies that bind to a glycodelin epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce a glycodelin monoclonal antibody of the invention are also disclosed herein. Kits comprising one or more of the disclosed glycodelin monoclonal antibodies and for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for a glycodelin epitope of a disclosed monoclonal glycodelin antibody and methods of using these polypeptides in the production of glycodelin antibodies are also encompassed by the present invention.
Type:
Grant
Filed:
July 27, 2012
Date of Patent:
July 2, 2013
Assignee:
TriPath Imaging, Inc.
Inventors:
Robert L. Cheek, Eric P. Dixon, Timothy J. Fischer, John W. Groelke, Steven L. Knapp, Stephen G. Simkins, Clark M. Whitehead
Abstract: Assays for detection of bactericidal anti-Neisserial antibodies using a factor H polypeptide having a human amino acid sequence that mediates binding to Neisserial factor H binding protein (fHBp) are provided, as well as non-human animal models of Neisserial infection.
Type:
Grant
Filed:
August 26, 2009
Date of Patent:
July 2, 2013
Assignees:
Children's Hospital & Research Center Oakland, Novartis Vaccines and Diagnostics, SRL, The University of Massachusetts
Inventors:
Dan M. Granoff, JoAnne Welsch, Sanjay Ram
Abstract: There is provided a method for determining whether a subject has a bacterial infection comprising: identifying an abnormal expression of one or more of CD49e, CD 14, CD11c, CD49f, and CD29 on leucocytes in a sample obtained from the subject; wherein an abnormal expression of CD49e, CD 14, CD11c, CD49f or CD29 is indicative of the subject having a bacterial infection.
Abstract: The invention relates to an isolated polypeptide of the luminal domain of synaptic vesicle glycoprotein 2C of Homo sapiens wherein at least 70 percent of the amino acid sequence is identical to the amino acid sequence of the SV2C of Homo sapiens. The polypeptide binds the HC fragment of botulinum neurotoxin A provided that the polypeptide is not the synaptic vesicle glycoprotein 2C of Homo sapiens.
Type:
Grant
Filed:
October 30, 2006
Date of Patent:
July 2, 2013
Assignee:
Toxogen GmbH
Inventors:
Stefan Mahrhold, Johannes Wilhelm Bigalke, Andreas Rummel, Thomas Binz
Abstract: The present invention relates to a method for detecting molecular interactions in a solution. In particular, the present invention relates to a method for detecting interactions between two substances that are likely to interact with one another. The present invention can be used in particular in the field of scientific research and in the field of medical analysis.
Abstract: A versatile drug testing device (a lateral flow diagnostic testing device) includes a flat transparent carrier with a top and a bottom with the carrier having a series of independent parallel grooves formed therein running from adjacent to the top to adjacent to the bottom of the carrier, each groove having a first opening and a second opening above the first opening therein adjacent to the bottom of the carrier, at least one drug test strip installed in one of said grooves with its absorbent pad contiguous to the openings and a cover layer attached to the carrier operable to sealing close each of said grooves whereby the bottom of the device can be immersed in a specimen of “urine”, “body fluid” or “other biological specimen” to wet the pad of the at least one test strip though the ingress of the specimen though the associated openings and the test results on the test strip can be easily viewed through the transparent carrier.